Saptarshi Banerjee

Saptarshi Banerjee

Auto-generated profile, based on publicly available information

Saptarshi Banerjee

Department of Radiotherapy, Medical College and Hospital, Kolkata, West Bengal, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2022 in Asian Journal of Pharmaceutical and Clinical Research
Verified
Journal Article
Open access
PDF file
SDSharmistha Daripa
Sharmistha Daripa
SBSaptarshi Banerjee
Saptarshi Banerjee
ASAparajita Sadhya
Aparajita Sadhya
ABAnjan Bera
Anjan Bera
Objectives: The benefit of concurrent chemoradiation is often not achievable due to poor tolerance due to increased toxicity, which is a common problem in our setting, where a significant portion of carcinoma cervix patients presents at an elderly age, with medical comorbidities, and with poor performance status. In addition, many patients refuse chemotherapy. Accelerated radiation therapy remains one of the possible alternatives there. Hence, we would like to perform a prospective study to compare treatment results between Pure Accelerated Radiation versus Concomitant Chemoradiation in Locally Advanced Squamous Cell Carcinoma of Cervix. Methods: After the initial investigative work, a total of 62 histologically confirmed squamous cell carcinoma of cervix locally advanced stage (FIGO-stage IB2 to IVA.) with ECOG performance status 0–2 patients were randomized into two arms: Arm A (Study arm, n=30) – Patients received Six fractions per week of External Beam Radiotherapy without chemotherapy and Arm B (Control arm, n=32) patients received concurrent chemoradiation with Five fractions per week of radiation with Weekly Injection of Cisplatin at the dose of 40 mg/m2. Results: Overall response rates between the two arms were similar and statistically not significant (p=0.352). All acute late toxicities are similar in both arms except acute renal toxicity which is more in the control arm and the difference is statistically significant (p=0.005). Conclusions: In developing countries like India with limited treatment facilities, pure accelerated RT with brachytherapy, without concurrent chemotherapy, may be a good option and it can be viewed as an equally effective option for the elderly patients, the patients who refuse, those who have contraindications for chemotherapy, or have comorbidities. Further, multicenter, controlled, and Phase III trials will be needed to prove the benefit of the shortening overall treatment time and compare the efficacy with chemoradiation.

7 July 2022 in Asian Journal of Pharmaceutical and Clinical Research
Verified
Journal Article
Open access
PDF file
CBChandrima Banerjee
Chandrima Banerjee
SBSaptarshi Banerjee
Saptarshi Banerjee
SDShatarupa Dutta
Shatarupa Dutta
ABAnjan Bera
Anjan Bera
Objectives: This study intended to explore the outcome, and toxicities of neoadjuvant chemotherapy in addition to standard treatment concomitant chemoradiation in locally advanced cervix cancer. Methods: Sixty-two (n=62) locally advanced cervical carcinoma patients were randomized into two arms: The controlled arm (30 patients) received concomitant chemoradiation with external beam radiation therapy of 50 Gy to the whole pelvis and Inj. Cisplatin (40 mg/m2/week) alone and the study arm (32 patients) received three cycles, neoadjuvant chemotherapy with Inj. Paclitaxel (175 mg/m2), and Inj. Cisplatin (75 mg/m2) at 3 weekly intervals, followed by concomitant chemoradiation with external beam radiation therapy (EBRT) of 50 Gy to whole pelvis and Inj. Cisplatin (40 mg/m2/week). Responses to treatment, toxicities, disease-free survival, and progression-free survival (PFS) were analyzed in both arms. Results: Among the total of 62 patients, 30 were in the concomitant chemoradiation alone arm and 32 were in neoadjuvant chemotherapy followed by the concomitant chemoradiation arm. The median follow-up period was about 13 months. The tumor response in the form of complete or partial responses was equivalent in the two arms. The disease-free survival and the PFS were also comparable in both arms. The acute and the late toxicities were also comparable in the two arms. Conclusions: This study showed that neoadjuvant chemotherapy with paclitaxel and cisplatin before definitive concomitant cisplatin-based chemoradiation can be used as an alternative in the management of locally advanced carcinoma of the cervix.

7 September 2022 in Asian Journal of Pharmaceutical and Clinical Research
Verified
Journal Article
Open access
PDF file
SDShatarupa Dutta
Shatarupa Dutta
SBSaptarshi Banerjee
Saptarshi Banerjee
ABAnjan Bera
Anjan Bera
SMSrikrishna Mandal
Srikrishna Mandal
CBChandrima Banerjee
Chandrima Banerjee
Objectives: Medullary breast carcinoma is a very rare subtype of invasive ductal carcinoma breast which accounts for about 1–7% of all breast carcinoma. The natural history of this uncommon histological subtype is unknown because of the lack of adequate reported data in the literature and the rare variety of this tumor. In our retrospective analysis, we have tried to identify demographic clinicopathological features and treatment outcomes of this rare subtype. Methods: Between January 2012 and December 2017, total of 1271 breast carcinoma cases were identified, and clinic pathological, demographic profile, and treatment received were recorded from the medical records file. American joint committee on Cancer tumor, node, and metastasis system was used for staging. Results: Out of 1271 breast carcinomas, 19 histologically confirmed medullary carcinoma cases were identified and constitute about 1.5% of the total case. About 78% of patients were with Stage II and Stage III disease at the time of diagnosis. Eleven patients were initially treated with MRM followed by adjuvant chemotherapy and radiotherapy. Eight patients received neoadjuvant chemotherapy followed by surgery and radiotherapy. In addition to cytotoxic chemotherapy, two patients received trastuzumab also. None of the patients received hormone therapy as all the patients were hormone receptor-negative. Conclusions: Out of all invasive carcinoma, approximately 1.5% of cases were medullary carcinoma. About 90% of cases were triple-negative. Triple-negative breast cancer is usually associated with poor outcomes but medullary carcinoma despite being triple-negative, patients with medullary carcinoma have a good chance of long-term survival.

1 June 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
FLFaidra Laskou
Faidra Laskou
TAT. Aung
T. Aung
DGD. Gayford
D. Gayford
SBS. Banerjee
S. Banerjee
CCC.S. Crowson
C.S. Crowson
BDB. Dasgupta
B. Dasgupta
Background The dreaded complication of giant cell arteritis (GCA), irreversible sight loss (SL), is present in 15%–25% of patients at diagnosis. This is likely due to delayed presentation, recognition and treatment. Fast track pathways for urgent assessment of suspected GCA reduce SL with associated cost savings. Information regarding the burden of SL in GCA is required to guide health strategy and has been explored in this UK wide study. Methods This is a prospective observational multi-centre study of visual involvement attributable to GCA. Demographic, disease features and treatment information was collected on all patients with new or relapsing GCA with or without visual symptoms (VS) or SL.SL was defined as symptomatic loss of acuity, field of vision or diplopia ascribable to ischaemic complications of GCA. Patients with transient VS were not considered to have SL. Analyses were performed using chi-squared and rank sum tests. Results Patients were predominantly female (274/388) and Caucasian; 3 non-Caucasian(Asian British, Black/Afro-Caribbean and Turkish).VS were present in 135/388 patients (35%) from 19 UK sites. Of patients with VS, these were transient or intermittent SL (n=9,7%), diplopia (n=33,24%), blurred vision (n=17,13%), flashing lights (n=4,3%) and eye pain (n=7,5%). Transient or permanent loss of acuity occurred in 92 patients (48 anterior ischaemic optic neuropathy [AION], 6 central retinal artery occlusion [CRAO],1 posterior ischaemic optic neuropathy, all attributed to GCA);1 hemispheric retinal vein occlusion, 1 branch retinal artery occlusion, 1 peri-papillary haemorrhage, 1 vitelliform dystrophy macula.8 had oculomotor nerve palsies(NP)(1 bilateral 3rd,1 bilateral 6th and 6 unilateral 3rd or 6th NP). Patients with VS were older than those without(mean ±SD age 75.9±9.3 and 73.5±8.5 respectively, p<0.001). Patients with VS had less headaches (p=0.012) and scalp tenderness (p=0.05) but more frequently tongue claudication (p=0.014), shorter symptom duration (3.9±5.5 days, p=0.001), lower CRP although not statistically significant(p=0.059), were less likely to meet ACR criteria and to improve than those without VS (p<0.001). No association was found with comorbidities or deprivation index.SL in 54 (40%) patients was due to AION or CRAO. Transient CRAO or AION was described in 17 and 30/47 (64%) had permanent SL (data missing from 7 patients). Patients with AION/CRAO were older (80.9±6.7 years) than those without AION/CRAO (73.3±8.7 years, p<0.001). They had shorter symptom duration (4.2±7.0 days, p=0.024), less likely to improve than those without AION/CRAO (p<0.001), less likely to have headaches (p<0.001) or polymyalgic symptoms (p=0.002), and more likely to have jaw claudication (p=0.043) and hypertension (p=0.002). Only 7 had diplopia on presentation. 5 patients experienced AION as manifestation of recrudescing disease. Conclusions VS often leading to SL in GCA requires urgent management. Patients with VS were older, without ‘typical symptoms’ such as headache and polymyalgia but more likely to have ischaemic symptoms such as jaw and tongue pain and hypertension. Recognition of VS associated features should be embodied in public and professional awareness programs to prevent permanent SL in GCA. Disclosure of Interest None declared

1 June 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
FLFaidra Laskou
Faidra Laskou
FCF. Coath
F. Coath
SMS. Mackie
S. Mackie
SBS. Banerjee
S. Banerjee
TAT. Aung
T. Aung
BDB. Dasgupta
B. Dasgupta
Background Diagnosis of Giant Cell Arteritis(GCA) is difficult since its manifestations are protean1. Under-diagnosis is associated with ischaemic complications whereas over diagnosis is associated with inappropriate glucocorticoids (GC)2.GCA is diagnosed by different specialties, including family physicians, who would benefit from a clinical prediction score.A fast track pathway also requires clinical triage in terms of probability of disease. We evaluated all referred patients (08/16–08/17) to develop a pre-test probability score(PTBS) to support a diagnostic pathway and decision-making. Methods The PTBS was generated from long standing clinical experience. Information collected at initial assessment was given varying positive weightage. This included baseline demographics (age-gender), symptomatology at presentation(onset, headache and scalp tenderness, ischaemic symptoms, constitutional symptoms, polymyalgia),C-Reactive protein(CRP) and examination findings(ischaemic ophthalmic complications, temporal artery abnormalities, extra-cranial abnormalities, cranial nerve palsies). Negative weightage was given for competing diagnoses (infection, cancer, head and neck pathology, systemic rheumatological diseases). The PTBS was compared with the final diagnosis as GCA or non-GCA 6 months after the initial assessment. Analysis was performed in Stata SE, version 13.1. Results 122 PTBS were collected of which CRP was missing in 1 case which was excluded from the analysis.23 had a final diagnosis of GCA at 6 months follow up. The rest consist our control group(99 patients). The area under the ROC curve for the 121 cases was 0.953 (figure 1). Using the bootstrap method gave an estimated area under the ROC curve (95% confidence interval) of 0.953 (0.911, 0.994). At the point of inflection, corresponding to a cut point of 9.5, sensitivity was 95.7%, and specificity was 86.7%;the likelihood ratio for a positive test was 7.2 and the likelihood ratio for a negative test, 0.050. At this cut point, 88.4% cases were correctly classified. Conclusions This single centre retrospective study suggests that PTBS is a useful standardised assessment tool for rating pre-test probability for GCA with high levels of sensitivity and specificity. PTBS may reduce variation in clinical assessment and aid decision making.A patient with low probability score(<9.5) can be managed with colour doppler ultrasound examination(US) which if negative will exclude the disease and the clinician can reassure patient.A patient with high PTBS and positive US can safely have the diagnosis confirmed and treated with GC. With intermediate scores, conflicting PTBS and US findings, equivocal US, additional investigations including TA biopsy and/or other imaging scans may be needed. Our results need validation in a prospective study and in internal and external validation cohorts. PTBS has the potential for forming the basis for education programme for the correct and early diagnosis of GCA and limit inappropriate GC in non GCA mimics. References [1] Murchison AP, et al. Validity of the American College of Rheumatology Criteria for the Diagnosis of Giant Cell Arteritis.Am J Ophthalmol2012Oct;154(4):722–9. [2] Elsideeg S, et al. SAT0293 Association between Clinical Presentation and Blindness in Gca and Effects of Gca-Related Visual Loss on Morbidity, Mortality and Quality of Life. Ann Rheum Dis2014Jun;73(Suppl 2):699.1–699. Disclosure of Interest None declared

7 September 2022 in Asian Journal of Pharmaceutical and Clinical Research
Verified
Journal Article
Open access
PDF file
SDShatarupa Dutta
Shatarupa Dutta
SBSaptarshi Banerjee
Saptarshi Banerjee
ABAnjan Bera
Anjan Bera
SMSrikrishna Mandal
Srikrishna Mandal
CBChandrima Banerjee
Chandrima Banerjee
Objectives: The importance and relevance of double primary are increasing with time as the increasing use of advanced diagnostic investigation and an increasing number of cancer survivors lead to an increase in double primary malignancy. Methods: We have collected data retrospectively from our own departmental patient’s record section from January 2011 to December 2021. All the details such as histopathology of both the malignancy, site of primary and secondary cancer, the time gap between the two cancer, clinical stage, and treatment received, along with demographic details have been recorded. Patients are divided into two categories either synchronous or metachronous when a second tumor develops either simultaneously or within 6 months of the diagnosis of the first tumor or 6 months after the diagnosis of the primary malignancy, respectively. Results: The total number of registered cases in one decade at our institute was 25,638 and among them were 41 double primary cases (0.16%). Twenty-two cases were metachronous (59%) and 19 cases (41%) were synchronous double primary. The most common site of double primary site was the head and neck region (38 %) followed by the lung, and esophagus (13% each), and the least common site was the colon (<1%). In the case of metachronous double primary, the mean time interval (the time gap between two cancer devolvement) was 7.4 years with a range of 2–19 years. The majority of the patients are treated with curative intention. Conclusions: The incidence of double primary is increasing over time. The management of double primary should be supervised by a multidisciplinary tumor board and more research is needed in the areas of epidemiology and treatment.